NDAINTRAVENOUSINJECTABLE1 Generic Approved
Approved
Jan 2005
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
21
Data completeness
4/8 — Partial
ELOXATIN (oxaliplatin) by Sanofi. Approved for platinum-based drug [epc]. First approved in 2005.
Drug data last refreshed 21h ago
Mechanism of Action
Pharmacologic Class:
Platinum-based Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Started Jun 2026
900 enrolled
Metastatic Pancreatic Ductal AdenocarcinomaPDAC
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
Started May 2026
66 enrolled
Colorectal Cancer
A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
Started Mar 2026
142 enrolled
HER2 IHC3+ Advanced Colorectal Cancer
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
Started Feb 2026
123 enrolled
HER2-positive Colorectal Cancer
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Started Apr 2025
50 enrolled
Lymphoma
Worked on ELOXATIN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.